The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- CDER Office Of Pharmaceutical Quality Manifesto Offers Manufacturing Flexibility As Potential Regulatory Upside Apr. 16, 2015
- TMC’s Cangrelor Approval Vote Based On FDA, Committee View That Drug Improves Current PCI Drug Practice Apr. 16, 2015
- CV Safety Confirmed For AZ, Takeda DPP4 Diabetes Drugs; New Labeling Urged For Potential Heart Failure Risk Apr. 15, 2015
See More Research Notes